<DOC>
	<DOCNO>NCT00042887</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Infusing chemotherapy drug directly bladder may kill cancer cell . It yet know surgery follow chemotherapy effective chemotherapy alone treat bladder cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy alone transurethral resection follow chemotherapy treating patient bladder cancer .</brief_summary>
	<brief_title>Chemotherapy With Without Surgery Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy chemoresection 4 weekly intravesical instillation mitomycin vs transurethral resection follow 1 instillation mitomycin patient low-risk superficial transitional cell carcinoma bladder . - Compare disease-free survival patient treat regimen . - Determine response rate 6 week patient treated chemoresection . - Determine percent patient tumor 6 week treat transurethral resection . - Compare quality life patient treat regimen . - Compare side effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease status ( primary v recurrent ) participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo chemoresection intravesical instillation mitomycin weekly 4 week . - Arm II : Patients undergo transurethral resection follow within 1-6 hour intravesical instillation mitomycin . Quality life assess baseline , week 1 ( arm II ) , week 5 ( arm I ) , week 6 . Patients follow week 6 19 , every 6 month 3 year , annually 2 year . PROJECTED ACCRUAL : A total 1,000 patient ( 500 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm solitary primary recurrent papillary transitional cell carcinoma bladder Ta T1 Tumor great 2 cm diameter Negative urine cytology No suspicious lesion bladder require biopsy No tumor prostatic urethra upper urinary tract No prior history T1 G3 tumor , muscle invasive tumor ( T2 great ) , carcinoma situ PATIENT CHARACTERISTICS : Age 80 Performance status WHO 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other HIV negative No active intractable uncontrollable bladder infection No urethral stricture would preclude endoscopic procedure repeat catheterization No prior concurrent congenital acquire immune deficiency syndrome No prior concurrent malignancy except cure basal cell skin cancer intraepithelial cancer cervix No prior concurrent leukemia Hodgkin 's disease No concurrent disease general anesthesia contraindicate No psychological , familial , sociological , geographical condition would preclude study compliance Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy More 12 month since prior BCG vaccine Chemotherapy At least 1 year since prior mitomycin Endocrine therapy Not specify Radiotherapy No prior pelvic radiotherapy Surgery No prior organ transplant Other At least 3 month since prior intravesical treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>